NCT00949559View on ClinicalTrials.gov

Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Solid TumorsAdvanced Solid Tumors
Interventions
DRUG

EP-100

as a single agent administered intravenously twice weekly x 3 with 1 week off (total 28 days)

Trial Locations (2)

85258

TGEN Clinical Research Services at Scottsdale Healthcare, Scottsdale

85259

Mayo Clinic, Scottsdale

Sponsors
All Listed Sponsors
lead

Esperance Pharmaceuticals Inc

INDUSTRY